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Multilevel Regulation and Translational Switches in
Synthetic Biology
Margarita B. Kopniczky, Simon J. Moore, and Paul S. Freemont
Abstract—In contrast to the versatility of regulatory mecha-
nisms in natural systems, synthetic genetic circuits have been
so far predominantly composed of transcriptionally regulated
modules. This is about to change as the repertoire of foundational
tools for post-transcriptional regulation is quickly expanding.
We provide an overview of the different types of translational
regulators: protein, small molecule and ribonucleic acid (RNA)
responsive and we describe the new emerging circuit designs
utilizing these tools. There are several advantages of achieving
multilevel regulation via translational switches and it is likely
that such designs will have the greatest and earliest impact in
mammalian synthetic biology for regenerative medicine and gene
therapy applications.
Index Terms—Biomedical engineering, circuit design, logic
devices, protein, ribonucleic acid (RNA), riboswitch, synthetic
biology, translation.
I. INTRODUCTION
S YNTHETIC Biology is an application-focused ﬁeld that isproviding a conceptual framework for engineering novel
biological systems based on the engineering principles of stan-
dardization, modularity and abstraction [1]. New functions ex-
tend the natural capabilities of cells by taking elements from
evolutionarily distant organisms or molecules designed entirely
de novo with potential applications in the ﬁelds of energy, agri-
culture, healthcare and manufacturing. However, there are only
a limited number of molecular mechanisms that can be used in
predictable and controllable ways to construct synthetic devices
[2], [3]. This lack of tools and modules makes it technically
challenging to design higher-level logic and implement mul-
tilevel regulation There are four main biological processes in
terms of circuit design that regulation can be imposed namely
at the transcription level, ribonucleic acid (RNA) degradation
level, the translational level and the protein degradation level.
Synthetic designed gene circuits predominantly use logical op-
erations carried out at the transcriptional level whereas natural
systems are regulated at all possible levels. It is estimated that
regulation at the translation level accounts for variability in gene
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expression by 40% [4], although in disagreement 9% variability
has also been reported [5].
Despite being ubiquitous in natural regulation, synthetic cir-
cuits are predominantly controlled by transcription in prefer-
ence to other levels of control [1]. The ﬁrst logic gates and
simple devices in synthetic biology were assembled from such
components: two repressing transcriptional modules can be as-
sembled into a toggle switch [6] and three such elements into a
repressillator [7]. The advantages of transcriptional regulation
are that there is remarkable ﬂexibility in the design space for
promoter sequences and DNA binding proteins and that known
modules can be composed into larger systems [8]. The response
of a promoter to various inputs can be changed by shufﬂing
its repressor binding sites [9], introducing point mutations into
its sequence [10] or screening randomized libraries [11]. Tran-
scription can be controlled via various modular RNA mediated
mechanism. Such examples include the CRISPR/Cas9 system,
[12], [13] and a new type of RNA-based transcriptional regula-
tors called small transcription activating RNAs [14].Moreover,
orthogonal synthetic TAL effector [15], [16] and zinc ﬁnger [17]
proteins have also been engineered. However, the complexity of
a circuit entirely relying on transcriptional regulation is limited
due to the loading effects, limited number of orthogonal regula-
tors, and the time that it takes to process each step of gene ex-
pression [18], [19]. Some transcriptional repressors exert their
effect by modifying the chromatin structure surrounding the
target region, such epigenetic effects can strongly delay the re-
activation of many transcriptional regulators [20], [17], [21].
In contrast, translational regulation possesses quicker dynamics
due to the ‘skipping‘ of the transcription step in gene expression.
In contrast, translational regulation processes have quicker dy-
namics due to the ‘skipping‘ of the transcription step in gene
expression. A decrease of burden can be achieved if RNA reg-
ulators are used instead of protein regulators of either transcrip-
tion or translation. Production of RNA is ‘cheaper` in terms of
nutrient requirements and does not divert ribosomal resources
away from the translation of other cellular proteins. Notwith-
standing, there is a greater need to broaden the range of avail-
able tools for post-transcriptional regulation [22], especially for
applications where a tightly controlled, predictable and reliable
circuitry is essential. In mammalian synthetic biology, the appli-
cation areas include recombinant protein production, post-trans-
lational modiﬁcations, stem cell reprogramming, gene therapy
and cancer cell detection and eradication [23], [24]. For such
applications, the space for error is narrow and small deviations
can lead to unwanted effects like therapeutic gene circuit de-
signed to identify and kill cancer cells could accidentally erad-
icate some healthy cells for example [25], [16]. Recently, there
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has been an increased effort to develop RNA based post-tran-
scriptional tools to indirectly inﬂuence translation via mRNA
stability and splicing or to directly control translation via inter-
fering with the recruitment of ribosomes [26], [27]. New devel-
opments in foundational technology for synthetic biology will
lead to fundamentally new circuit designs, with increasing so-
phistication and complexity. In this review, we focus on the new
tools available to directly regulate translation and we describe
some of the new emerging circuit designs that leverage these
tools.
II. BACKGROUND
Translation happens in fundamentally different ways in
prokaryotes and eukaryotes. In prokaryotes, translation gener-
ally takes place simultaneously with transcription, from mul-
tiple Open Reading Frames (ORFs) on polycistronic mRNA.
In contrast, this process is spatially separated in eukaryotes due
to the nucleus and nuclear envelope. To guide nascent mRNAs
into the cytoplasm, eukaryotes add a 7-methylguanylate cap to
the 5` end of the mRNA, before translation initiation factors
and ribosomes bind. The translation start site is deﬁned by the
Kozak sequence, which is equivalent – although evolutionary
distinct – to the Shine-Dalgarno Sequence (SDS) found in
prokaryotes. Apart from the 5’ capping process, eukaryotic
or viral mRNAs can use various independent mechanisms.
For example the internal ribosome entry site (IRES) [28], an
RNA element with stable secondary structure that is able to
either directly recruit ribosomes or bind initiation/elongation
factors. The most common start codon in all domains of life is
AUG, with various elongation factors to assist in the process
of translation.
Therefore, the approaches to control and regulate translation
in prokaryotes and eukaryotes are fundamentally different. In
prokaryotes, occluding the SDS from being recognised by the
ribosome is one approach and can be achieved by incorporating
a complementary region on the mRNA. In eukaryotes, more
sophisticated mechanisms can be designed, for example an
aptamer motif with stable secondary structure or a protein
binding site upstream of the start site. Eukaryotic mRNAs
are normally monocistronic (contain a single ORF) but it has
been observed that a second ORF can be translated if an IRES
element is present or if an elF4 initiation factor is recruited
upstream of the start site. As discussed later, some regulatory
elements or parts of regulatory elements can be used to interfere
with translation in prokaryotes and eukaryotes, but they have
to be implemented according to different design rules.
III. PREDICTING TRANSLATION INITIATION RATE
A key aspect of translational regulation is in deﬁning the ef-
ﬁciency of translation which helps to ﬁne-tune protein levels.
In a recent study, the efﬁciency of 65,536 human translation
initiation sequences (TIS), the sites in close proximity to the
start codon, were compared and TIS de-regulation was found
to be associated with cancer genesis [29]. Analogous to the set
of constitutive promoters of predictable strengths [10], libraries
of elements with increasing translation efﬁciencies have been
constructed. In prokaryotes, it is well established that the trans-
lation rate depends greatly on the sequence complementarity
Fig. 1. Various features of mRNA that modulate translation efﬁciency on a
continuous scale. The features are shown in the 5’ region, upstream of the
open reading frame (ORF) which is labeled as is the poly-A tail at the 3’
end of the mRNA. (a) Cap-dependent mechanisms include stem-loop RNA
structures which interfere with ribosomal scanning; upstream ORFs (uORFs)
cause ribosomes to dissociate from the mRNA at the associated stop codon and
therefore reduces translation of the second ORF; TIS (Translation Initiation
Sequence) variants involved in the direct recognition of the translation start site
by the ribosome. (b) Variants of cap-independent IRES sequences inﬂuence
the afﬁnity of ribosomes or initiation factors to the mRNA, thus affecting
translation efﬁciency (number of protein molecules produced from an mRNA
over time).
of the SDS to the ribosome and on the secondary structure of
the mRNA [30]. Various algorithms have been developed to de-
sign an RBS of desired strength for a given ORF to minimize
complex secondary structure formation and optimize ribosomal
binding, which are easily accessed through various web-based
resources [31]–[35]. The RBS calculator for example has a 47%
probability of predicting RBS strength within two-fold of the
target [34]. Therefore it is proposed to generate multiple ele-
ments and screen for the desired activity since the probability in-
creases to 72%, 85% and 92% if two, three or four RBSs are gen-
erated. Recently, Mutalik et al. proposed a novel and modular
bicistronic RBS design and achieved an improved, 93% chance
of predicting RBS strength within two-fold of target [11].
Designing ﬁne-tuned translation responses can allow the con-
trol of relative gene expression from the samemRNA transcript,
or transcripts from similar promoters. The strategy to modify
RBS strengths of ORFs encoding genes involved in a biosyn-
thetic pathway was successful to optimize naringenin produc-
tion for example [36]. Similar control over translation efﬁciency
is highly desirable in mammalian synthetic biology for opti-
mizing therapeutic protein production, programming reliable
differentiation for tissue engineering or for achieving optimal
gene expression dosage in gene therapy. Variations in TISs can
be used to ﬁne tune translation efﬁciency in mammalian cells,
but only within a limited dynamic range and thus is restric-
tive for translational control (Table I.). To address this, Ferreira
et al. assembled a library of upstream ORFs (uORF), which
made it possible to span a range of three orders of magnitude
in translation efﬁciency when used together with TIS predic-
tion [37]. An uORF is a sequence in 5‘ from the main ORF
that encodes a short peptide that may be functional in certain
cases [38]. According to the proposed probabilistic leaky scan-
ning model, ribosomes that initiate and exit translation at the
uORF are more likely to dissociate from the mRNA than the
fraction of ribosomes that `leaks through’ and only initiates at
the correct start codon [37]. Alternatively, RNA structures can
also be used to decrease translation efﬁciency in a systematic
and predictable manner via the mechanism of blocking elonga-
tion and thus slowing overall translation rate [39], [40].
Not only cap-dependent but also cap-independent translation
efﬁciency can be modiﬁed. One of the most commonly used
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TABLE I
TOOLS FOR TRANSLATION INITIATION RATE PREDICTION
IRESs, the Encephalomyocarditis virus IRES was mutated to
produce a library of 24 variants spanning a 300-fold expression
range, which were validated across multiple cell types and genes
[41]. This approach is useful for the production of antibodies by
establishing an optimal light-heavy chain production ratio
IV. REGULATION WITH RNA BINDING PROTEINS
Some proteins, or domains of proteins, can bind RNA with
high speciﬁcity and afﬁnity, and are therefore ideal for crafting
control of translation in a synthetic biology context. Some of
these RNA Binding Proteins (RBPs) have a structural role in
assisting ribosome assembly [42] or as viral coat proteins [43],
whilst others are involved in RNA regulation in organelles [44]
and many play a key part in translation regulation as their nat-
ural function [45]. The human genome contains 424 known and
predicted RNA Binding proteins, which are involved in mul-
tiple processes [46], whilst many bind to evolutionary conserved
RNA recognition motifs [47]. Novel approaches in bioinfor-
matics and high-throughput sequencing facilitate the identiﬁca-
tion of RBPs expressed differentially in various cell types and
identifying the RNA sequences that they recognize [48].
RBPs can be classiﬁed in various ways. Here, for simplicity,
we distinguish Motif Binding Proteins (MotBPs), and Repeat
Proteins (RPs). MotBPs recognize speciﬁc RNA sequence ele-
ments (motifs), often with distinct secondary structures. RPs in
contrast, contain repeated domains, each of which is responsible
for binding a single nucleotide on the target RNA. Both MotBPs
and RPs hold vast potential for the regulation of translation and
other RNA-related processes in synthetic biology [49].
Many MotBPs exist in eukaryotes but it has generally proven
difﬁcult to engineer them for novel uses in synthetic biology.
The RNA recognitionmotifs can be found in hundreds of human
proteins [50] and efforts have been made to create libraries from
such eukaryotic MotBPs. However, they remain difﬁcult to sys-
tematically design due to the substantial variation in the RNA
binding surface and the number of bases (2–8) recognized [51].
Instead, viral and prokaryotic MotBPs are preferred for use in
eukaryotic synthetic biology. They possess an added advantage
of being evolutionary distant (orthogonal) and are therefore less
likely to interfere with endogenous eukaryotic processes.
Viral and prokaryotic MotBPs often recognize structural mo-
tifs, usually a hairpin, where binding speciﬁcity is typically de-
ﬁned by the residues at the end and internal loops [52], [53].
RNA motif MotBP pairs provide an ideal tool for regulatory
modules in the design of complex synthetic circuits because
the RNA motif is well deﬁned and amenable to engineering,
since the binding residues can be mapped accurately using pro-
tein crystallography and homology modelling. An interesting
MotBP category includes synthetically evolved RNA aptamer
binding domains [54]. Nucleic acid aptamers can be generated
via the technique called systematic evolution of ligands by ex-
ponential enrichment (SELEX) [55]. An increasing number of
SELEX derived RNA ligands have been developed for various
applications [56]. RNA aptamers binding endogenous proteins
may be integrated into synthetic designs in an analogous way to
viral/prokaryotic MotBP-RNA motif pairs (Fig. 2) [57].
A. MotBPs as Translational Repressors
The simplest application of an MotBP is its use as a repressor
to block translation upon binding to its cognate RNA motif in
the 5’ untranslated region (UTR) of a gene of interest [Fig. 2(a)]
[58], [59]. Multiple investigations observed that the position of
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Fig. 2. RNA motif binding proteins (MotBP) can be used either as translational repressors (turn OFF translation) or as activators (turn ON translation). (a) In
a simple repressor design, the MotBP (blue) binds to its cognate RNA motif (blue) positioned in the 5’ untranslated region (UTR) of the mRNA in order to
control expression of a downstream open reading frame (ORF) followed by the poly-A tail at the 3’ end of the mRNA. (b) Negative feedback circuit designed to
control the expression of an RNA motif binding protein (MotBP; blue) fused protein of interest shown as a ﬂuorescent protein (FP; yellow) in this example [64].
(c) Reversible repression via a MotBP (green) binding a small molecule (yellow) which dissociates the MotBP from the mRNA [54]. (d) Two different MotBP
binding sites (blue and orange) in the 5‘UTR lead to the repression of translation in the presence of either MotBP (blue or orange). (e) Inverter module based on
RNA degradation induced via the translation of a bait ORF (bORF) with premature termination codons (black box). The internal ribosome entry site (IRES) driven
ORF is only expressed if the MotBP (blue) binds and represses the bORF and the mRNA is thus spared from degradation [68]. (f) Protein-protein interaction
mediated translation initiation from the second ORF (ORF2) of mRNA. Ribosomes dissociate from the mRNA after the translation of the ﬁrst ORF (ORF1) but
can be recruited again in the presence of elF4 (brown). This is achieved via a fusion protein of elF4 and a light-responsive protein (green) which is recruited to the
mRNA upon blue light illumination via binding of a cognate partner (green) fused to a MotBP (blue) [63]. (g) Cytoplasmic localization of an otherwise membrane
bound MotBP fusion-protein induces translation from ORF2 preceded by the MotBP‘s cognate RNA motif (blue) [70].
the RNA motif within the 5’UTR is critical and that the max-
imum translation activity decreases as the distance of the struc-
tural motif to the 5’ cap decreases, both inmammalian cells [60],
[61] and in plants [59]. However, the same context dependency
was not observed in yeast [62]. Moreover, multiple copies of
the RNA motif can increase repression, with a maximum level
observed with three [61] or six [63] tandem copies of RNA mo-
tifs. Interestingly, different modes of repression can often be ob-
served with different MotBPs, some inhibiting only cap-depen-
dent translation, and others inhibiting translation from an entire
bicistronic transcript where the second ORF is translated from
an IRES [45]. Such complex design rules make the systematic
engineering of translational modules challenging and thus thor-
ough characterization of the individual parts are necessary.
A general strategy was proposed to stabilize gene expression
levels via incorporation of an MoBP mediated negative feed-
back loop at the translational level [64]. The L7Ae MotBP was
fused to a ﬂuorescent reporter and placed under the control of
its cognate RNA motif. In such a conﬁguration, the binding
afﬁnity of the MotBP to the RNA motif regulates the steady
state level of theMotBP fusion protein. Furthermore, the param-
eters inferred from experimental measurements and the model
describing this regulatory circuit could be extended to predict
regulation of translation from other mRNAs in trans. The L7Ae
protein and the RNA motif could potentially be replaced with
any knownMotBPs and RNAmotifs with different dissociation
constants, and the MotBP could be fused to or regulate any pro-
tein of interest.
Another widely used transcriptional regulator is the tetra-
cycline repressor (TetR) protein which has recently been en-
gineered to achieve small molecule inducible translation [54].
The repressor protein binds to an artiﬁcially selected RNA ap-
tamer motif to block translation in the same way as discussed in
the previous examples. When tetracycline analogues are added,
TetR changes conformation and dissociates from the mRNA,
allowing translation to happen. The method was initially devel-
oped for applications in model organisms where the tools for
controlling gene expression are limited. More recently it was
used to control the expression of various target proteins, inde-
pendent of promoter context and mRNA localization in plas-
modium to reveal anti-malarial drug targets [65].
Combination of MotBPs may also be used to carry out bio-
computation. The expression of MotBPs can be under the con-
trol of different promoters that sense small molecule inputs and
then transmit these input signals to regulate translation of the
output signal. The MS2 and L7Ae protein-RNA motif pairs
were used in the construction of such a half-adder and half-sub-
stractor circuits [66]. An important feature for the construction
of the half-adder (Fig. 3) circuit was that a single ORF can be
controlled by multiple MotBPs if multiple RNA motifs are in-
serted into the same 5’UTR [66]. The ORF will only be trans-
lated if none of the MotBPs are present in the cell [Fig. 2(d)].
MotBP mediated translation control can also be combined with
transcriptional regulation in a modular fashion and also with ri-
bozyme regulation. Ausländer et al. constructed a three input
AND gate by composing promoter regulation, an MotBP and a
protein-responsive hammerhead ribozyme [67]. These two ex-
amples demonstrate that MotBP repressors are useful tools in
combination with other regulatory elements to achieve higher-
order control dynamics of complex synthetic biology circuits.
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Fig. 3. The synthetic biology design features of the half-adder circuit by
Ausländer et al. [66] can be abstracted to a logic gate circuit diagram. Logic
gates can represent any type of regulation where an output is produced in
response to one or multiple inputs. The types of logic gates in the above circuit
include: NOT gates which only produce output if input is absent (represented
by triangular symbols), AND gates which produce output if both inputs are
present (half-oval symbol) and a NOR gate which produces output if neither of
the inputs is present (ﬁsh-shaped symbol). The circuit design can be divided
into transcriptional and translational components. The transcriptional level is
regulated by two small molecules (Phloretin and Erythromycin) which repress
the transcription of two reporter genes (dsRed and EYFP) and two RNA
motif binding proteins (MotBP) genes, this repression is represented by NOT
gates. The translational level includes unregulated steps, indicated by black
boxes for the translation of two different MotBPs (orange and blue). The YFP
reporter can be produced via two independent routes; there are two possible
YFP-mRNAs (yellow) with two different MotBP binding motifs upstream of
the YFP coding sequence (blue and orange). YFP is only produced if either
variant of YFP-mRNA is present, and its cognate regulator MotBP (blue or
orange) is not present. Therefore, a sequential NOT and AND gates represents
this relationship. The DsRed reporter is only produced if neither of the MotBPs
is present (NOR gate), the DsRed mRNA (red) is constitutively transcribed.
The overall resulting function is a half-adder, a circuit where the outputs
depended on the inputs according to the truth table in the bottom right.
B. MotBPs as Translational Activators
Several attempts have been made to achieve MotBP medi-
ated induction. A set of ON switches was constructed from
three different MotBPs by converting the basic OFF switch in
a cis-acting setup where the inverter module is found on the
same mRNA [68] [Fig. 2(e)]. The MotBP regulates the expres-
sion of a small peptide (152 a.a.) from a bait ORF that is termi-
nated by two premature termination codons (OFF switches). If
translated, the endogenous Nonsense Mediated Decay (NMD)
response [69] is activated to degrade the entire mRNA. NMD is
a general eukaryotic RNA surveillance mechanism, which tar-
gets certain mRNAs, such as those containing premature termi-
nation codons for degradation. If the translation of the bait ORF
is inhibited because of binding of the MotBP to the RNA motif
just upstream, the NMD is not activated, correct splicing of the
mRNA can occur and IRES mediated translation can proceed
from the second ORF. The second ORF is the reporter gene or
any gene of interest that is inserted as part of a circuit design.
An alternative approach to switching on translation in re-
sponse to MotBP binding, involves the elF4 translation initi-
ation factor, which has the role of recruiting ribosomes to the
mRNA. It is known that a second ORF on a eukaryotic mRNA
is not translated unless some sequence element is present up-
stream to recruit initiation factors or the ribosomes directly.
Not only can an IRES element instigate this, the recruitment
of elF4 initiation factor alone, via any mechanism, is enough
to initiate translation. ElF4 can be fused to a MotBP and thus
the fusion protein will induce translation from a second, oth-
erwise untranslated ORF that contains a cognate RNA binding
motif upstream. In order to achieve pharmacological induction,
a multi-protein fusion was constructed from aMotBP, elF4F and
an H-Ras [Fig. 2(g)] [70]. H-Ras is normally a membrane-as-
sociated signaling protein but it can dissociate in the absence
of a speciﬁc protein-modiﬁcation. Some therapeutically inter-
esting small molecules such as FTI-277 can inhibit this modi-
ﬁcation and thus H-Ras is delocalized from the membrane into
the cytoplasm. Thus, the fusion protein can initiate translation
from the second ORF of the reporter construct. The method has
been proposed for use in drug-screening but it could theoreti-
cally be adapted to sense the delocalization of any protein of
interest from the membrane to the cytoplasm.
A similar approach to the translational activator module
above was utilized in a design to achieve the light induced
translation from the second ORF of an mRNA [63] [Fig. 2(f)].
Blue light illumination induces the CRY2PHR protein to bind
CIBN protein and this protein-protein interaction provides the
molecular basis for the sensor circuit. The MotBP was fused to
the CIBN, the elF4E to the CRY2PHR and therefore translation
was induced from a second ORF containing the cognate RNA
motif of the MotBP. Such a design may allow linking transla-
tion output to any chosen protein-protein interaction input in
general.
C. Repeat Proteins
While complex synthetic circuits can be assembled using
MotBPs and their corresponding RNA motifs in a modular and
orthogonal fashion, their greatest limitation is that they cannot
be adapted to target any desired endogenous RNA sequence. In
order to interface a synthetic circuit with endogenous RNAs,
repeat proteins are a plausible solution. Repeat proteins have
been likened to DNA binding transcription activator-like effec-
tors (TALEs) since they also have a one-to-one code of domain
to amino acid recognition code [71]. The two known classes
of repeat proteins are Pumilio and Fem–3 mRNA-binding
factor (PUF) proteins and Pentatricopeptide Repeat Proteins
(PPRs). Some expect that they will become just as important in
manipulating RNA as TALES and Zinc Finger domain proteins
are for manipulating DNA [49], [72].
PUF repeat proteins typically consist of eight tandem repeats
of three-helix bundles that form a crescent-shaped structure. The
amino acids at positions 12 and 16 within the second –helix
deﬁne the speciﬁcity of each repeat, according to a recognition
code [73]. Natural PUFs usually recognize 8–9 nucleotides in
an anti-parallel orientation and are not particularly diverse –
humans only have two such proteins (PUM1 and PUM2) [74],
[75]. Custom PUF domains have been used to both up and down
regulate translation. In a system similar to that in Fig. 3(f),
and by the same research group, light inducible translation was
achieved via PUF regulation [76]. In another work, the site spe-
ciﬁc addition or removal of the polyA tail was regulated by
PUF domains fused to effectors, to inﬂuence translation efﬁ-
ciency and mRNA half-life, in a sequence-dependent manner
[77]. Like other RBPs, repeat proteins can be utilized for various
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other RNA-related regulatory mechanisms when fused to other
functional domains – examples that have been implemented in-
clude tracking localization and alternative splicing [78]. The re-
cent developments in modular assembly of designer PUF do-
mains [79] and attempts to increase the number of nucleotides
recognized for increased speciﬁcity [80] are likely to facilitate
their use in an increasing number of applications.
A phylogeneticaly distinct class of repeat proteins, PPRs are
one of the largest nucleic acid binding protein families in land
plants and bind to a great diversity of RNAmolecules [44]. They
are nuclear encoded but typically targeted to organelles and are
known to be involved in translational stability and splicing con-
trol. PPRs bind RNA in a parallel orientation and each domain
consists of about 35 amino acids and folds into a pair of antipar-
allel -helices. The recognition code is deﬁned by two amino
acids, one at the beginning and one at the end of each domain
[81]. In contrast with PUFs, the number of bases that natural
PPRs can recognize is not ﬁxed and can be between two and
thirty [49]. This ﬂexibility and versatility makes PPRs espe-
cially favorable for engineering. In a recent work, Coquille et
al. created a modular consensus PPR scaffold with optimized
properties for synthetic biology applications [82]. This opens
up the possibility of exploring the potential of PPRs in a great
variety of ways for RNA manipulation [83].
V. REGULATIONWITH SMALLMOLECULES VIA RIBOSWITCHES
Riboswitches provide a fascinating ancestral link to the most
primitive forms of life [84]. They represent an elegant but
simple mechanism for controlling genetic regulation, using
a direct interaction of a small molecule ligand to an RNA
aptamer. This allows an organism to sense intracellular levels
of a small molecule and respond accordingly. For example,
in Bacillus subtillis approximately 4% of the genome is regu-
lated by riboswitches [85], whilst it is estimated that between
10–15% of bacterial genomes encode non-coding RNA that
play diverse roles in regulation [86]. From an engineering per-
spective, riboswitches offer a powerful tool for the development
of diverse sensory circuits, logic gates and bi-phasic switches.
Since the initial discovery of the thiamine pyrophosphate
(TPP) riboswitch just over a decade ago [87], [88] a plethora
of ligand-RNA regulatory systems have been identiﬁed in
prokaryotes [89]–[91] and a ﬁnite list have been unveiled in
plants [92], algae [93] and fungi [94]. Predominantly located
in the 5’UTR of mRNA, riboswitches form a complex tertiary
structure upon transcription and folding, forming a pocket
whereby a small-molecule can bind. This ligand-aptamer inter-
action induces a conformational rearrangement to control gene
expression. The range of ligands is restricted to biochemical
intermediates of central metabolism [84], [89], [95], and ions
[96]–[98].
A. Riboswitch Control Mechanisms, Discovery and Diversity
The binding of a ligand to the core of a riboswitch initiates a
conformational rearrangement in the RNA tertiary structure to
affect gene expression [89]. In general riboswitches possess an
aptamer (ligand binding or sensor domain) and an expression
platform (anti-terminator and terminator stems). Although in
terms of nucleotide sequence context, these two domains are
Fig. 4. Riboswitch mechanisms. Prokaryotic mechanisms include
(a) transcription control provided by a terminator (orange) that stalls RNA
polymerase extension in the presence of the small molecule ligand (blue). In
the absence of the ligand complementary regions indicated with red form an
antiterminator structure. (b) Translation initiation is prevented by masking of
the RBS (green) inside the terminator stem-loop (orange) in the presence of
the repressor ligand (blue). (c) Anti-sense sRNA (upper molecule) control of
orthogonal genes in trans. A complementary region to the 5’ sequence of the
mRNA (orange) is revealed and inhibits translation upon ligand (blue) binding
to the aptamer on the sRNA. (d) RNA splicing control is unique to eukaryotes,
with a riboswitch positioned within an intron (dashed line) to hinder splicing
in response to ligand binding.
effectively interconnected through complementary stem-loops.
The aptamer (sensor) is the only element that is conserved
between different species [99], whereas the expression platform
(or transducer) is variable and linked to the mechanism of reg-
ulation. For a comprehensive review of riboswitch regulatory
mechanisms, see [84]. In brief, binding of a ligand to an RNA
aptamer initiates a structural rearrangement to control formation
of a terminator complex that controls gene expression [100].
For control of translational initiation, the terminator overlaps
the RBS, thereby masking access for ribosome docking (Fig. 4).
Binding of the ligand to the aptamer domain can either switch
gene expression ON or OFF, depending on the requirements of
the cell. Alternatively, transcription termination is controlled
by a terminator, which in bacteria is normally followed by
a poly-U sequence, which destabilises the RNA polymerase
during transcription [101]. This method of regulation offers
several advantages over translational control. The inherent
turnover of mRNA (especially in prokaryotic systems) during
transcription allows riboswitches to provide a dynamic online
response through various stages of cellular growth. Firstly,
less resources are required if gene expression is aborted before
complete mRNA synthesis, whilst complete control can be
offered for polycistronic operons, therefore preventing the
buildup of intermediates and redundancy in a complex pathway.
A third category of regulation has recently been discovered,
showing a coenzyme riboswitch that controls expression of
a non-coding anti-sense sRNA [102]–[104]. Finally, conserved
eukaryotic TPP riboswitches utilize a unique RNA splicing
mechanism to control expression of thiamine biosynthetic
genes [105], [106] [Fig. 4(d)]. It is likely that these latter two
examples of riboswitch regulation are widespread in nature.
However, developments in riboswitch discovery in eukaryotes
are recent and are likely to be expanded.
For discovering new and alternative examples of known
riboswitches, a number of search algorithms are available
(Table II). The earliest example is the Mfold algorithm, which
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TABLE II
SOFTWARE TOOLS FOR RIBOSWITCH PREDICTION
uses the minimal free energy principle for predicting RNA
secondary structure [107]. In addition, a number of web-based
tools speciﬁc for riboswitch prediction from an input DNA
sequence are available. This includes the Denison Riboswitch
Detector [108], Riboswitch Explorer [109], RNA-PATTERN
[110], RNAMotif [111], RiboSW [112], Riboswitch ﬁnder
[113] and CMﬁnder [114]. These examples provide a prediction
output based on conserved examples of known riboswitch
classes. However, the search algorithms used are restricted
on sequence length. For wider discovery, more sophisticated
algorithms and rapid characterization techniques [115] are
required due to the need to search larger amounts of genomic
data. Experimental methods like SHAPE-Seq allow structural
characterization in a high-throughput manner and may facilitate
the investigation of new riboswitch classes [116]. For example,
the conserved MoCo (molybdenum/tungsten) motif [98] and a
number of unclassiﬁed riboswitches [91] suggest a broader role
in regulation. However, some of the ligands themselves may be
unknown at our current level of understanding.
An alternative strategy for creating novel riboswitch func-
tions is to engineer a characterized riboswitch framework ei-
ther through minor modiﬁcations or replacement of the aptamer
or expression platform domain. The rise of SELEX [55], [56]
has demonstrated a high-throughput screening method for ob-
taining novel RNA aptamers with afﬁnity for a chosen ligand.
However, transplanting the synthetic designs into a natural ri-
boswitch has been difﬁcult to achieve [117]. From a structural
perspective, engineering of synthetic riboswitchesmay require a
similar approach to de novo protein design [118]. At the current
level of understanding, the easier approach lies with modifying
single RNA residues of a starting aptamer in order to achieve
binding of a new ligand similar to the original. Thus, the re-
sult is an altered aptamer with recognition highly speciﬁc to the
new ligand but not binding the original ligand. A key example
of constructing an orthogonal aptamer-ligand pair with this ap-
proach was the engineering of the adenine (purine) riboswitch
control element [119]. This rationale provides a route to enable
the synthetic engineering of metabolic pathways. In theory, with
further development, this ﬁne tuning approach can providemod-
ular control for the transformation of a substrate into its product
via a number of controlled intermediates. This could be used for
ﬂux control to prevent accumulation of toxic intermediates and
decrease burden due to excess protein expression.
B. Circuit Design
An interesting circuit with great potential that relies on a
prokaryotic translational riboswitch, is the Riboselector [120].
This device provides a selective advantage in response to in-
conspicuous metabolites and can be applied to directed evolu-
tion of high producing metabolic pathways. Another promising
tool in circuit design are sets of orthogonal riboswitches that
can be employed to independently tune gene expression levels
from genes in the same operon [121]. Such a strategy can be
utilized in optimizing the ratio of metabolic enzymes expressed
in a biosynthetic pathway.
Riboswitches and related ribozymes are an attractive tool for
eukaryotic and in particular mammalian synthetic biology cir-
cuit design. However, the design and application of advanced,
predictable and ﬁnely tuned RNA sensing devices is still in
the early stages of development. A riboswitch can provide a
wide dynamic range in respect to ligand concentration [122].
Riboswitch elements can be used as key bottleneck ﬁlters to
prevent unnecessary accumulation of metabolic intermediates
in an engineered biosynthetic pathway. One possible area of in-
terest is for the control of post-translational modiﬁcations in re-
combinant protein maturation, where homogeneity is a funda-
mental requirement, especially with therapeutic antibodies. Al-
ternatively, an RNA based biosensor that could detect accumu-
lation of undesirable metabolites or act as an active response to a
depletion of essential cellular resources. A handful of synthetic
examples have recently been demonstrated, which includes the
use of a synthetic tetracycline riboswitch in yeast [123] and a
tetracycline ribozyme in HeLa cells to induce gene expression
[117]. A Biotin binding aptamer was inserted into the 5’UTRs
of mammalian transcripts and resulted in a 10-fold repression
of translation upon the presence of the small molecule [124].
Furthermore, a couple of studies have highlighted that natural
riboswitch aptamers can be replaced with synthetic versions in
a modular fashion and applied as an induction tool in eukaryotic
expression systems [125].
VI. RNA-RNA RIBOREGULATION
An mRNA can not only fold onto itself to form various
secondary structures and bind small molecules but it can also
bind other single stranded complementary RNA molecules,
according to Watson-Crick base pairing. Such trans-acting
RNAs (taRNA) can be used to regulate translation in a variety
of ways. The classic examples in prokaryotes rely on blocking
either the SDS [126] or the Start codon [127]. In addition,
refactoring of the RNA-IN/OUT system of E. coli has also
yielded a set of orthogonal riboregulators of translation [128].
In eukaryotes, as described above, it is less straightforward to
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stop or induce translation via an RNA-RNA interaction only. In
the yeast antiswitch system a taRNA contains a small molecule
responsive aptamer and switches conformation upon tetracy-
cline inducer binding [129]. The sequence complementary to
the Initiation site of the target mRNA is exposed and translation
is repressed (turned OFF). It is known that micro RNAs can
directly down-regulate translation and that miRNA binding
sites are sometimes found in the 5‘UTRs of mRNAs [130].
However, in synthetic constructs the miRNA binding sites are
usually positioned at the 3’UTR and induce the degradation
of the target via the RNA interference pathway [131], [132].
A simple MotBP OFF switch [Fig. 2(a)] can effectively be
inverted if the RNA binding motif is integrated into a taRNA
which induces degradation of the target mRNA only when
the MotBP is absent [133], [131]. Other new methods exist
to regulate RNA degradation in an RNA-regulated fashion.
The Cas9/CRISPR technology has risen in popularity as it is a
sequence-speciﬁc and very versatile tool for transcriptional reg-
ulation. Recent research has proven the concept that a modiﬁed
Cas9, R-Cas9 can be used to selectively target RNA instead
of DNA and target it for degradation [134]. This mechanism
could potentially be modiﬁed to manipulate RNA in other ways
than degradation.
VII. MODELLING TRANSLATION
Mathematical models of translation of increasing complexity
have been developed as a consequence of our increasingly de-
tailed understanding of the underlying molecular mechanisms.
A wide variety of mathematical modelling approaches have
been employed to understand the interaction of a synthetic
gene construct with the host organism to inform the design
of optimized gene expression systems and reviewed in [135],
[136]. Furthermore, along with the development of molecular
tools for dynamic control of translation, there is an increasing
need for computational models to aid the design of regulatory
modules based on translational switches.
In Section III, we have outlined how translation initiation
rates are an important rate limiting step in gene expression and
can be a key point of gene regulation for synthetic biology de-
sign [31]. However, in addition to the initiation step, the elon-
gation and termination steps are also important to include when
modelling translation. The ﬁrst models that incorporated these
three steps of translation used non-linear Ordinary Differential
Equation (ODE) based kinetics which could capture changes in
elongation rate along a mRNA due to its secondary structure
[137] or polysome size (ie. multiple ribosomes) [138]. Further
details of endogenous regulation via initiation factors were dis-
covered and these could be incorporated into more detailed ki-
netic models [139], [140]. The effect of codon composition was
also incorporated into a design tool for optimizing protein ex-
pression [141].
Some aspects of translation, such as the movement of ribo-
somes causing collisions and ‘trafﬁc jams’ are difﬁcult to cap-
ture by deterministic models. The ﬁrst stochastic model of trans-
lation by Mitrai et al. attempts to captures this [142]. A sim-
ilar underlying framework was extended and adapted to model
metabolic burden effects on the cell arising from the competi-
tion for a common pool of ribosomes [143].
A few examples exist where modelling was used to aid the
design of devices assembled from various cis- and transacting
control elements described in Sections IV–VI. Stapleton et al.
constructed a negative feedback circuit from a MotBP protein
(see Section IV) and an ODE based kinetic model was utilized to
predict its behavior [64]. A mechanistic model was also imple-
mented to describe the behavior of a type of ligand responsive
RNA element [144] and stochastic simulations were correlated
to the experimental observations from a set of designs assem-
bled from such components.
In summary the most widely used model for translation is
based around codon optimization which is used extensively in
industry, for optimizing gene/protein expression. Other models
are used to provide increasing insights into host – synthetic gene
interactions and to help the design of complex regulatory sys-
tems.
VIII. CONCLUSIONS
It has recently become possible to predict translation efﬁ-
ciency on a continuous scale and to switch translation ON and
OFF, similar to how transcription can be induced or repressed.
With the increasingly versatile toolbox available to synthetic bi-
ologists, it is becoming possible to implement multi-level bi-
ological circuits and achieve higher-level computation. Novel
translational control mechanisms will greatly facilitate such ef-
forts and will likely rise in popularity for circuit design, espe-
cially in mammalian cells.
There are multiple features of translational regulation that
make it an especially attractive approach for being used in mam-
malian gene circuits. Firstly, they allow completely independent
regulation from those sequence elements that are responsible for
regulation at the DNA-level. Once mRNA is transcribed, the
promoter and genomic context surrounding the synthetic con-
struct on the DNA level becomes irrelevant. Therefore, transla-
tional regulation can be integrated with traditional control sys-
tems in a modular fashion, as demonstrated by the complex
half-adder (Fig. 3) and half-subtractor circuits implemented in
mammalian cells [66].
Second, the dynamics of translational regulation are faster
than that of the full gene expression process. The re-activation
of a previously repressed mRNA can happen much faster than
that of a transcriptionally repressed gene. Furthermore, many
of the currently used transcriptional repressors often involve
epigenetic modiﬁcations that take time to reverse, thus leading
to slow reactivation. Not as fast as signaling cascades based
on post-translational regulation, but generally faster than tran-
scriptional regulation, translational regulation may be the ideal
choice for regulating processes on the medium timescale, such
as feedback regulation to balance protein levels in therapeutic
or metabolic circuits [64].
Thirdly, translational regulation can be directly interfaced
with various cytoplasmic components of the cell. RNA ap-
tamers that are known to bind endogenous proteins or small
molecules may directly be utilized and incorporated into pro-
tein or small molecule responsive translational switches [57].
The ﬁrst examples of useful circuits with a translational switch
at their core are cancer cell classiﬁers which can detect the
level of endogenous proteins ( -catenin and NF-kB) involved
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in carcinogenesis [57]. Signal inputs from cytoplasmic pro-
tein-protein interactions or protein localization can be directly
utilized as an input for translational regulation [63], [76], [62].
Finally, the metabolic burden imposed on the cell may be al-
leviated via ﬁne tuning translation, since the competition for
translational resources is generally greater than the competi-
tion for transcriptional resources [145]. Modelling and exper-
imentally comparing burden effects on chassis cells, related to
various modes of circuit regulation achieving similar function
may greatly inform the design cycle of synthetic genetic circuits
[146].
As synthetic genetic circuits becomemore sophisticated, they
will employ a combination of transcriptional and various post-
transcriptional regulators. There are an increasing number of
new tools for translational regulation with many future applica-
tions in mammalian synthetic biology. In order to facilitate their
widespread use, it is essential that such new tools are thoroughly
characterized, the design rules are explored and part libraries be-
come freely available to the synthetic biology community.
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